{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-050029","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2023-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.589838+00:00","generated_at":"2026-06-13T21:34:21.682550+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Scott Brun, M.D., appointed to Jasper Board as R&D Committee Chair; Klein resigns","bullets":["Scott Brun, M.D., appointed as Class I director effective June 20, 2023; chairs R&D Committee, serves on Compensation Committee.","Dr. Brun has over 20 years pharma R&D leadership, including AbbVie, Abbott, and Horizon Therapeutics.","Lawrence Klein, Ph.D., resigned effective June 20, 2023, due to his recent appointment as a Partner at Versant Ventures.","Vishal Kapoor appointed to Audit and Compensation Committees.","Dr. Brun receives initial option grant of 94,000 shares vesting over 4 years under Director Compensation Policy."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-050029","json":"https://secwatch.observer/filing/0001213900-23-050029.json","markdown":"https://secwatch.observer/filing/0001213900-23-050029.md","text":"https://secwatch.observer/filing/0001213900-23-050029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023050029/0001213900-23-050029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023050029/ea180573-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T21:34:21.682550+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"959d4f3a6f","claim":"Scott Brun was appointed as Class I Director at Jasper Therapeutics, Inc..","evidence_excerpt":"Effective June 20, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Scott Brun, M.D., as a Class I director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023050029/0001213900-23-050029-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}